Amyris, Inc. (NASDAQ:AMRS) will be releasing its earnings data after the market closes on Wednesday, November 8th. Analysts expect Amyris to post earnings of ($0.77) per share for the quarter.

Amyris (NASDAQ:AMRS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.06) by ($0.35). The firm had revenue of $25.68 million during the quarter, compared to analyst estimates of $23.68 million. The business’s revenue was up 167.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.06) earnings per share. On average, analysts expect Amyris to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Amyris, Inc. (NASDAQ AMRS) opened at $3.19 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.65 and a debt-to-equity ratio of -0.76.

Several brokerages have recently issued reports on AMRS. ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Cowen and Company set a $4.00 price target on Amyris and gave the company a “hold” rating in a report on Thursday, August 17th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Amyris in a report on Tuesday, September 26th. Finally, Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.69.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Earnings History for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.